

NHS Lanarkshire
Template for Clinical Protocol for Introduction of New Medication

1. Medicine name & formulation

- Tirzepatide solution for injection in pre-filled pen (Mounjaro®)

2. Licensed Indications

Weight management, in conjunction with dietary measures and increased physical activity in individuals with a BMI of 30 kg/m² or more, or in individuals with a BMI of 27 kg/m² or more in the presence of at least one weight-related co-morbidity.
(Also licensed for management of Type 2 diabetes - not relevant to this submission)

3. Summary of National Guidance

SMC guidance (Jun '24)

For use in adults with BMI ≥ 30 kg/ m²* and at least one weight-related co-morbidity (*a lower BMI may be appropriate for certain ethnic minority groups).

[SMC guidance](#)

NHS Scotland consensus statement: national criteria for the prioritisation of GLP1RA and GLP1RA/GIPRA for the treatment of obesity in NHS Scotland (Sept 24)

First phase of implementation of SMC guidance should be patients who have a BMI ≥ 38 kg/ m² in the presence of at least one weight-related comorbidity

[NHS Scotland consensus statement](#)

4. Please Define Application for Use

For use in eligible patients taking part in a Weight Management Tier 3 behaviour change intervention, in conjunction with the intervention.

5. Proposed place in therapy in Lanarkshire. Please attach protocol which should include details of: *See "Use of Tirzepatide, obesity", also attached*

6. Anticipated patient numbers per annum

- Around 140 patients per annum will be suitable for treatment with either Mounjaro® or Wegovy® (see previous submission). This is because there is capacity for around 140 patients to attend a Tier 3 weight management behaviour change intervention per annum. All will meet the SMC criteria and Scottish National Consensus criteria, although some will have contra-indications/previous adverse reaction to treatment, and some will develop adverse reactions/be non-responders and discontinue treatment.

NHS Lanarkshire
Template for Clinical Protocol for Introduction of New Medication

	<p>Service implications</p> <p>Impact on nursing/medical duties – for specialist use/recommendation only. The LWMS employs a specialist nurse and consultant who will provide education and follow up for these patients.</p> <p>Impact on pharmacy duties – initial prescribing will be undertaken by the LWMS prescribers through secondary care pharmacy. Once titration has taken place, patients are stable on full dose treatment, and shown to be responding, prescribing will be handed back to primary care. Prescribing of needles will require to be undertaken by primary care throughout the treatment period as these are unavailable through secondary care pharmacy. (This is the same arrangement as was in place for the preceding pharmacotherapies for obesity).</p> <p>Impact on laboratory & imaging services – Nil</p> <p>Where will patients be treated? – reviewed / initiated / recommended by specialist weight management clinicians at their community or secondary care sites.</p> <p>Has business plan been submitted? – A business plan has been submitted for Wegovy® and Mounjaro® and it has been agreed that this pathway will be used for the initial phasing out of medication for the management of obesity.</p>
7.	<p>Cost implications</p> <p>For a patient to titrate up to the full dose over 24 weeks is £642. If they remain on that dose for a full year it would cost £1496. Subsequent years at full dose would cost £1586 per annum, however it is not anticipated this dose will be required for maintenance. This is slightly more expensive than Wegovy®. (£1301 for the first year, and £1430 for subsequent years).</p>
8.	<p>Form Prepared by:</p> <ul style="list-style-type: none"> • Isabel Howat, Secondary care clinical lead, Lanarkshire Weight Management Service
9.	<p>Endorsed by Professional Grouping:</p> <p>Name & signature of lead clinician: Dr Isabel Howat</p> <p>Date: 02/12/2024</p>